FiercePharmaAs IPO nears, J&J eyes $40B valuation for consumer health unitApr 24, 2023Kevin DunleavyBy Kevin Dunleavymore_vert
The Wall Street JournalJ&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market - WSJApr 23, 2023Corrie Driebusch & Peter LoftusBy Corrie Driebusch & Peter Loftusmore_vert
Barron'sJ&J’s Kenvue Spinoff: A Rare IPO Winner in a Moribund MarketApr 28, 2023Andrew BaryBy Andrew Barymore_vert
BloombergJ&J's $43 Billion Spinoff Brings Band-Aid, Tylenol to Hurting IPO MarketApr 25, 2023Liana B. BakerBy Liana B. Bakermore_vert
CNBCJohnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPOApr 24, 2023Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
CNBCJohnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report saysApr 24, 2023Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
Barron'sJ&J's Spinoff Kenvue Valued at $40 Billion. What's Ahead for Consumer Health.Apr 25, 2023Josh Nathan-kazisBy Josh Nathan-kazismore_vert